ABOS vs. CADL, DSGN, AMRN, ACB, LRMR, OCGN, GLUE, DMAC, SCPH, and CTNM
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Candel Therapeutics (CADL), Design Therapeutics (DSGN), Amarin (AMRN), Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), DiaMedica Therapeutics (DMAC), scPharmaceuticals (SCPH), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.
Acumen Pharmaceuticals vs. Its Competitors
Candel Therapeutics (NASDAQ:CADL) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
In the previous week, Candel Therapeutics had 9 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 10 mentions for Candel Therapeutics and 1 mentions for Acumen Pharmaceuticals. Candel Therapeutics' average media sentiment score of 0.18 beat Acumen Pharmaceuticals' score of -0.13 indicating that Candel Therapeutics is being referred to more favorably in the media.
Candel Therapeutics' return on equity of -41.00% beat Acumen Pharmaceuticals' return on equity.
Candel Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Candel Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Candel Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 300.40%. Acumen Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 416.61%. Given Acumen Pharmaceuticals' higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Candel Therapeutics.
Candel Therapeutics has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Candel Therapeutics beats Acumen Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ABOS) was last updated on 9/4/2025 by MarketBeat.com Staff
Free ABOS Stock Alerts